HK82597A - Use of a tetrahydrocarbazolone derivative for the manufacture of medicaments - Google Patents

Use of a tetrahydrocarbazolone derivative for the manufacture of medicaments Download PDF

Info

Publication number
HK82597A
HK82597A HK82597A HK82597A HK82597A HK 82597 A HK82597 A HK 82597A HK 82597 A HK82597 A HK 82597A HK 82597 A HK82597 A HK 82597A HK 82597 A HK82597 A HK 82597A
Authority
HK
Hong Kong
Prior art keywords
sub
sup
compound
methyl
active ingredient
Prior art date
Application number
HK82597A
Other languages
German (de)
English (en)
Inventor
Brian Tyers Michael
Harold Coates Ian
Cedric Humber David
Blanch Ewan George
Angus Bell James
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40347948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK82597(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HK82597A publication Critical patent/HK82597A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (5)

  1. Utilisation de la 1,2,3,9-tétrahydro-9-méthyl-3-[(2-méthyl-1H-imidazole-1-yl)méthyl]-4H-carbazole-4-one ou d'un sel physiologiquement acceptable ou d'un hydrate de celle-ci pour la fabrication d'un médicament pour soulager les nausées et vomissements.
  2. Utilisation suivant la revendication 1, caractérisée en ce que la 1,2,3,9-tétrahydro-9-méthyl-3-[(2-méthyl-1H-imidazole-1-yl)méthyl]-4H-carbazole-4-one est sous la forme d'un chlorhydrate.
  3. Utilisation suivant la revendication 1, caractérisée en ce que la 1,2,3,9-tétrahydro-9-méthyl-3-[(2-méthyl-1H-imidazole-1-yl)méthyl]-4H-carbazole-4-one est sous la forme de son chlorhydrate.
  4. Utilisation suivant l'une quelconque des revendications 1 à 3 pour la fabrication d'un médicament à employer en combinaison avec un agent thérapeutique anti-cancer.
  5. Utilisation suivant la revendication 4, caracterisée en ce que l'agent thérapeutique est la cisplatine.
HK82597A 1985-06-25 1997-06-19 Use of a tetrahydrocarbazolone derivative for the manufacture of medicaments HK82597A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858516083A GB8516083D0 (en) 1985-06-25 1985-06-25 Heterocyclic compounds
GB868628474A GB8628474D0 (en) 1985-06-25 1986-11-28 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HK82597A true HK82597A (en) 1997-06-27

Family

ID=40347948

Family Applications (1)

Application Number Title Priority Date Filing Date
HK82597A HK82597A (en) 1985-06-25 1997-06-19 Use of a tetrahydrocarbazolone derivative for the manufacture of medicaments

Country Status (22)

Country Link
US (2) US4753789A (fr)
EP (2) EP0431443A3 (fr)
JP (2) JPS6253920A (fr)
AT (2) ATE134510T1 (fr)
AU (2) AU609028B2 (fr)
BE (1) BE1002249A4 (fr)
CA (1) CA1296637C (fr)
CH (1) CH672068A5 (fr)
CY (1) CY2000A (fr)
DE (2) DE3650488T2 (fr)
DK (1) DK624687A (fr)
FR (1) FR2613934B1 (fr)
GB (3) GB8516083D0 (fr)
HK (1) HK82597A (fr)
IE (1) IE60908B1 (fr)
IL (1) IL84638A (fr)
IT (1) IT1211937B (fr)
NL (1) NL8702853A (fr)
NZ (1) NZ222743A (fr)
SE (1) SE8704747L (fr)
SG (1) SG43311A1 (fr)
ZA (1) ZA878927B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0385517B1 (fr) * 1985-03-14 1993-04-14 BEECHAM GROUP plc Médicaments pour le traitement du vomissement
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
JP2608078B2 (ja) * 1986-12-17 1997-05-07 グラクソ、グループ、リミテッド 医 薬
GB8630080D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB8630079D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
JPH0754759B2 (ja) * 1987-04-27 1995-06-07 日本電信電話株式会社 プラズマ処理方法および装置並びにプラズマ処理装置用モード変換器
US4943428A (en) * 1987-07-10 1990-07-24 Wright State University Stimulation of serotonin-1A receptors in mammals to alleviate motion sickness and emesis induced by chemical agents
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
GB8816187D0 (en) * 1988-07-07 1988-08-10 Glaxo Group Ltd Medicaments
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
AU627221B2 (en) * 1988-09-27 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Pyridoindole derivatives and processes for preparation thereof
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5039528A (en) * 1989-12-11 1991-08-13 Olney John W EAA antagonists as anti-emetic drugs
US4971651A (en) * 1990-02-05 1990-11-20 Hitachi, Ltd. Microwave plasma processing method and apparatus
WO1993000075A1 (fr) * 1991-06-26 1993-01-07 Sepracor, Inc. Methodes et compositions pour le traitement des vomissements, de la nausee et d'autres troubles faisant appel a l'ondansetron optiquement pur s(-)
CA2112487C (fr) * 1991-06-26 2003-04-15 James W. Young Methode et compositions pour le traitement des vomissements, des nausees et d'autres troubles a l'ondansetron optiquement pur r(+)
EP1082959A1 (fr) * 1991-09-20 2001-03-14 Glaxo Group Limited Utilisation des NK1-antagonistes pour le traitement de la depression
JPH08507514A (ja) * 1993-03-08 1996-08-13 藤沢薬品工業株式会社 脳血管性疾患を治療または予防するための薬物
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
WO2000051582A2 (fr) 1999-03-01 2000-09-08 Sepracor Inc. Procedes de traitement de l'apnee et de troubles de l'apnee a l'aide de r(+) ondansetron optiquement pur
RU2162695C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона гидрохлорида дигидрата, субстанция и фармацевтический препарат
KR100434390B1 (ko) * 2001-04-20 2004-06-04 안국약품 주식회사 1,2,3,9-테트라히드로-9-메틸-3-[(2-메틸-1ｈ-이미다졸-1-일)메틸]-4ｈ-카바졸-4-온을 유효성분으로 하는 비강분무용조성물
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
AU2004204827B2 (en) * 2003-01-13 2006-06-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7288660B2 (en) * 2004-05-07 2007-10-30 Taro Pharmaceutical Industries Limited Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
WO2006105117A2 (fr) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Procede destine a traiter des troubles et des conditions au moyen d'inhibiteurs et d'antagonistes a peripherie restreinte
CA2666512C (fr) * 2006-10-24 2014-05-27 Helsinn Healthcare S.A. Capsules molles comprenant du chlorhydrate de palonosetron ayant une stabilite et une biodisponibilite ameliorees
JP2010050046A (ja) 2008-08-25 2010-03-04 Hitachi High-Technologies Corp プラズマ処理装置
AU2010343147A1 (en) 2009-12-28 2012-07-19 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
MX342993B (es) 2013-04-25 2016-10-13 Inst Mexicano Del Petróleo Proceso de obtencion de copolimeros aleatorios derivados del acido itaconico y/o sus isomeros y alquenil sulfonatos de sodio y uso del producto obtenido.
EP3589369A4 (fr) * 2017-01-09 2020-03-18 DAS-MG, Inc. Utilisation et composition pour traiter la myasthénie grave et d'autres syndromes myasthéniques

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040489A1 (fr) * 1980-05-17 1981-11-25 FISONS plc Mélanges, sels, emballages et compositions pharmaceutiques contenant l'acide 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyrane-2-carboxylique ou un de ses dérivés et une antihistamine antagoniste des récepteurs H2
BE894285A (fr) * 1981-09-04 1983-03-02 Glaxo Group Ltd Composition pharmaceutique contenant un medicament anti-inflammatoire et de la ranitidine ou un sel de ce compose
FR2557110B1 (fr) * 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
HU193592B (en) * 1984-01-25 1987-11-30 Glaxo Group Ltd Process for producing tetrahydro-carbazolone derivatives
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
DE3680123D1 (en) * 1985-01-23 1991-08-14 Glaxo Group Ltd Tetrahydrocarbazolonderivate.
EP0385517B1 (fr) * 1985-03-14 1993-04-14 BEECHAM GROUP plc Médicaments pour le traitement du vomissement
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8630079D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
IL84638A (en) 1992-05-25
NL8702853A (nl) 1988-06-16
AU8191487A (en) 1988-06-02
DE3650488T2 (de) 1996-09-05
AU609028B2 (en) 1991-04-26
IE873230L (en) 1988-05-28
FR2613934A1 (fr) 1988-10-21
IT8748643A0 (it) 1987-11-27
GB2200046B (en) 1990-09-26
JPS6253920A (ja) 1987-03-09
DE3740351A1 (de) 1988-06-09
GB2200046A (en) 1988-07-27
ATE134510T1 (de) 1996-03-15
SG43311A1 (en) 1997-10-17
SE8704747D0 (sv) 1987-11-27
GB8628474D0 (en) 1987-01-07
DK624687D0 (da) 1987-11-27
DK624687A (da) 1988-05-29
US4929632A (en) 1990-05-29
SE8704747L (sv) 1988-05-29
IE60908B1 (en) 1994-08-24
BE1002249A4 (fr) 1990-11-06
NZ222743A (en) 1991-09-25
JPS63198623A (ja) 1988-08-17
EP0226266A2 (fr) 1987-06-24
AU616386B2 (en) 1991-10-31
EP0431443A3 (en) 1991-09-18
AU6703786A (en) 1988-06-30
ATA312587A (de) 1992-05-15
US4753789A (en) 1988-06-28
CA1296637C (fr) 1992-03-03
IT1211937B (it) 1989-11-08
ZA878927B (en) 1988-10-26
FR2613934B1 (fr) 1993-07-09
AT395374B (de) 1992-12-10
GB8727836D0 (en) 1987-12-31
CH672068A5 (fr) 1989-10-31
DE3650488D1 (de) 1996-04-04
EP0226266B1 (fr) 1996-02-28
GB8516083D0 (en) 1985-07-31
JPH0324447B2 (fr) 1991-04-03
CY2000A (en) 1997-12-05
EP0431443A2 (fr) 1991-06-12
EP0226266A3 (en) 1990-01-24

Similar Documents

Publication Publication Date Title
EP0226266B1 (fr) Utilisation d'un dérivé du tétrahydrocarbazolone pour la fabrication de médicaments
US5578628A (en) Medicaments for the treatment of nausea and vomiting
EP0216555B1 (fr) Utilisation de dérivés de la dioxopipéridine pour le traitement de l'anxiété, pour la réduction des niveaux de la sérotonine ou de l'acide 5-hydroxy-indoleacétique chroniquement anormalement élevés dans le cerveau, et pour le traitement des infections bact
EP0615751B1 (fr) Utilisation d'antagonistes de tachykinines dans le traitement du vomissement
JPH0555484B2 (fr)
EP0559297B1 (fr) Utilisation des dérivés hétérocycliques pour la manufacture des médicaments
US4835173A (en) Method of medical treatment
US5098909A (en) 5-ht3 receptor antagonists for treatment of cough and bronchoconstriction
US5240954A (en) Medicaments
US3885035A (en) Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
EP0552205B1 (fr) Nouvelle utilisation medicale pour un certain derive d'indole et composition pharmaceutique le contenant
US5482716A (en) Medicaments
JP2834175B2 (ja) 医 薬
CA2100777C (fr) Composition pharmaceutique contenant du granisetron et de la dexamethasone
EP0411900A2 (fr) Médicaments pour le traitement de la boulimie
EP0269452A2 (fr) Application de dérivés de cétone pour la fabrication de médicaments
US5221687A (en) Medicaments
US5276050A (en) Medicaments
JPH0827000A (ja) 悪阻による諸症状の予防または治療薬
JPH10152442A (ja) 抗肥満剤
JPH0827001A (ja) 術後嘔吐の予防または治療薬
JPH01250319A (ja) 医薬

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20060623